JPRN-UMIN000009993已完成1 期
Phase I study on the feasibility of Nedaplatin plus S-1 combination therapy for squamous cell lung cancer. - Nedaplatin plus S-1 combination therapy for squamous cell lung cancer
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
Because of shortage of case accumulation, the study was terminated.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patient who have severe infection 2. Pregnant or lactating women. 3. Multiple cancer 4. A known history of allergy 5. A known history of GI bleeding 6. Patient who have interstitial pneumonia 7. Patient who have severe diabetes mellitus, liver cirrhosis, renal dysfunction, angina pectoris, arrhythmia, or myocardiac infarction before 3 months 8. Patient who have therapeutic need of pleural effusion, pericardiac effusion, or SVC syndrome 9. Patient who have obscure symptoms of brain metastasis. 10. Patient who have obscure symptoms of peripheral nerve dysfunction 11. Patient who take flucytosin.of brain 12. Patient who have severe 13.patient who is judged as an inappropriate case by the doctor in charge
研究者
相似试验
已完成
2 期
Phase II trial of neoadjuvant chemotherapy for unresectable liver metastasis of colorectal cancerColorectal cancer patients with unresectable liver metastasisJPRN-UMIN000006994Surgery, Kyorin university hospital10
已完成
2 期
Phase II study of nab-paclitaxel and carboplatin for elderly patients with non-small cell lung cancer. (KRSG1303)on-small cell lung cancerJPRN-UMIN000011534Kanto respiratory disease study group32
已完成
不适用
Basic analysis of new evaluation method in neoadjuvant chemotherapy (Additional study of phase II trial of neoadjuvant chemotherapy for unresectable liver metastasis of colorectal cancer)Colorectal cancer with unresectable liver mttastasisJPRN-UMIN000006995Surgery, Kyorin university hospital10
已完成
2 期
Efficacy and safety of weekly nab-paclitaxel plus CBDCA in patients with CUPcancer of unknown primaryCUP, nab-Paclitaxel,CBDCAJPRN-jRCTs051180084Yagi Toshinari17
已完成
2 期
Combination therapy with immune-cell therapy and immune check point inhibitormalignant tumorJPRN-jRCTc031190100Takimoto Rishu40